Grace Therapeutics (GRCE) Debt Ratio (2019 - 2021)
Grace Therapeutics' (GRCE) quarterly Debt Ratio came in at 0.0 in Q4 2021, down 99.25% quarter-over-quarter from 0.04 in Q1 2019.
Powered by 
Analysis
Grace Therapeutics (GRCE) Debt Ratio (2019 - 2021) Analysis & Trends
Grace Therapeutics has disclosed Debt Ratio across 2 years of filings, most recently posting 0.0 for Q4 2021.
- In Q4 2021, Debt Ratio changed N/A year-over-year to 0.0; the TTM figure through Dec 2021 stood at 0.0 (changed N/A YoY), while the FY2019 annual figure was 0.04, changed N/A from the prior year.
- Debt Ratio came in at 0.0 for Q4 2021 at Grace Therapeutics, down from 0.04 in the prior quarter.
- In the past five years, Debt Ratio ranged from a high of 0.04 in Q1 2019 to a low of 0.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 642.63 Bn | 621.87 Bn | 17.26 Bn | 0.30 |
| 2 | AbbVie | 449.10 Bn | 442.54 Bn | 12.70 Bn | 0.52 |
| 3 | Merck | 358.13 Bn | 350.98 Bn | 12.21 Bn | 0.42 |
| 4 | Novartis Ag | 267.47 Bn | 259.78 Bn | 11.24 Bn | 0.08 |
| 5 | Pfizer | 156.64 Bn | 144.94 Bn | 10.94 Bn | 0.31 |
| 6 | Sanofi | 52.15 Bn | 44.77 Bn | 10.79 Bn | 0.17 |
| 7 | Revolution Medicines | 42.84 Bn | 42.84 Bn | - | - |
| 8 | Incyte | 24.68 Bn | 20.15 Bn | 1.57 Bn | 0.00 |
| 9 | United Therapeutics | 21.47 Bn | 18.81 Bn | 683.80 Mn | - |
| 10 | Grace Therapeutics | 38.51 Mn | 38.51 Mn | - | - |